Biochemistry & Analytical Biochemistry

Effects and risks of beta-blocker in infantile hemangioma: A retrospective analysis

International Conference on Clinical Chemistry & Laboratory Medicine

October 17-18, 2016 Chicago, USA

Recher Morgan

Lille University, France

Posters & Accepted Abstracts: Biochem Anal Biochem

Abstract:

Background: Infantile hemangioma (IH) is a very common vascular tumor that affects up to 10% of newborns. Since 2008, oral propranolol is used to treat complicated IH, like hemangioma that obstruct vital structures or ulcerated hemangioma. Aim: To investigate, the therapeutic results and effects of propranolol on cardiovascular and biological parameters in infants to assess its safety. Methods: All pediatric patients with complicated IH who started systemic propranolol from February 2009 to December 2014 were included. 218 patients (155 girls and 63 boys) were treated by propranolol. Median age at beginning of treatment was 4.7 months (10 days to 6 years). The most frequent localization of IH was facial (63 patients), palpebral (52 patients), perineal (20 patients), labial (14 patients), airway obstruction (8 patients) and 1 PHACE syndrome. Median length of therapy was 7.5 months for facial IH, 6 months for palpebral, 5.6 months for perineal IH and 7 months for subglottic localization. Results: Adverse events were observed: hypoglycemia (n=11 patients aged less 6 months), arterial hypotension (n=103 patients, especially at the second and third dose with dose titration), bradycardia (n=120). Transthoracic echocardiography was realized in 158 patients: 19 pathologies were found (8 PDA, 4 ASD, 4 mitral regurgitations, 2 VSD, 1 coarctation). Other adverse events occurred in 49 patients (wheezing, acrocyanosis, diarrhea, sleep disturbance) leading to modification in management. Complete response was observed for all but 11 (partial or no response). Conclusion: We must be aware of frequent adverse events under beta-blocker in these patients.

Biography :

Email: morgan_recher@hotmail.frt